806 related articles for article (PubMed ID: 24768714)
21. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor.
Rong YP; Bultynck G; Aromolaran AS; Zhong F; Parys JB; De Smedt H; Mignery GA; Roderick HL; Bootman MD; Distelhorst CW
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14397-402. PubMed ID: 19706527
[TBL] [Abstract][Full Text] [Related]
22. Profiling of the Bcl-2/Bcl-X(L)-binding sites on type 1 IP(3) receptor.
Monaco G; Beckers M; Ivanova H; Missiaen L; Parys JB; De Smedt H; Bultynck G
Biochem Biophys Res Commun; 2012 Nov; 428(1):31-5. PubMed ID: 23058917
[TBL] [Abstract][Full Text] [Related]
23. Bcl-xL acts as an inhibitor of IP
Rosa N; Ivanova H; Wagner LE; Kale J; La Rovere R; Welkenhuyzen K; Louros N; Karamanou S; Shabardina V; Lemmens I; Vandermarliere E; Hamada K; Ando H; Rousseau F; Schymkowitz J; Tavernier J; Mikoshiba K; Economou A; Andrews DW; Parys JB; Yule DI; Bultynck G
Cell Death Differ; 2022 Apr; 29(4):788-805. PubMed ID: 34750538
[TBL] [Abstract][Full Text] [Related]
24. New functions of mitochondria associated membranes in cellular signaling.
van Vliet AR; Verfaillie T; Agostinis P
Biochim Biophys Acta; 2014 Oct; 1843(10):2253-62. PubMed ID: 24642268
[TBL] [Abstract][Full Text] [Related]
25. Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction.
Zhong F; Harr MW; Bultynck G; Monaco G; Parys JB; De Smedt H; Rong YP; Molitoris JK; Lam M; Ryder C; Matsuyama S; Distelhorst CW
Blood; 2011 Mar; 117(10):2924-34. PubMed ID: 21193695
[TBL] [Abstract][Full Text] [Related]
26. Ca(2+)-mediated regulation of VDAC1 expression levels is associated with cell death induction.
Weisthal S; Keinan N; Ben-Hail D; Arif T; Shoshan-Barmatz V
Biochim Biophys Acta; 2014 Oct; 1843(10):2270-81. PubMed ID: 24704533
[TBL] [Abstract][Full Text] [Related]
27. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals.
Rong YP; Aromolaran AS; Bultynck G; Zhong F; Li X; McColl K; Matsuyama S; Herlitze S; Roderick HL; Bootman MD; Mignery GA; Parys JB; De Smedt H; Distelhorst CW
Mol Cell; 2008 Jul; 31(2):255-65. PubMed ID: 18657507
[TBL] [Abstract][Full Text] [Related]
28. New Insights in the IP
Parys JB; Vervliet T
Adv Exp Med Biol; 2020; 1131():243-270. PubMed ID: 31646513
[TBL] [Abstract][Full Text] [Related]
29. At the right distance: ER-mitochondria juxtaposition in cell life and death.
Naon D; Scorrano L
Biochim Biophys Acta; 2014 Oct; 1843(10):2184-94. PubMed ID: 24875902
[TBL] [Abstract][Full Text] [Related]
30. The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP3 receptor inhibition.
Ivanova H; Ritaine A; Wagner L; Luyten T; Shapovalov G; Welkenhuyzen K; Seitaj B; Monaco G; De Smedt H; Prevarskaya N; Yule DI; Parys JB; Bultynck G
Oncotarget; 2016 Aug; 7(34):55704-55720. PubMed ID: 27494888
[TBL] [Abstract][Full Text] [Related]
31. Bcl-2 and IP
Ivanova H; Wagner LE; Tanimura A; Vandermarliere E; Luyten T; Welkenhuyzen K; Alzayady KJ; Wang L; Hamada K; Mikoshiba K; De Smedt H; Martens L; Yule DI; Parys JB; Bultynck G
Cell Mol Life Sci; 2019 Oct; 76(19):3843-3859. PubMed ID: 30989245
[TBL] [Abstract][Full Text] [Related]
32. Bcl-2 inhibitors as anti-cancer therapeutics: The impact of and on calcium signaling.
Vervloessem T; Kerkhofs M; La Rovere RM; Sneyers F; Parys JB; Bultynck G
Cell Calcium; 2018 Mar; 70():102-116. PubMed ID: 28705421
[TBL] [Abstract][Full Text] [Related]
33. Apoptosis protection by Mcl-1 and Bcl-2 modulation of inositol 1,4,5-trisphosphate receptor-dependent Ca2+ signaling.
Eckenrode EF; Yang J; Velmurugan GV; Foskett JK; White C
J Biol Chem; 2010 Apr; 285(18):13678-84. PubMed ID: 20189983
[TBL] [Abstract][Full Text] [Related]
34. Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP
Distelhorst CW; Bootman MD
Cold Spring Harb Perspect Biol; 2019 Sep; 11(9):. PubMed ID: 31110129
[TBL] [Abstract][Full Text] [Related]
35. The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca
Vervloessem T; Ivanova H; Luyten T; Parys JB; Bultynck G
Biochim Biophys Acta Mol Cell Res; 2017 Jun; 1864(6):968-976. PubMed ID: 27913204
[TBL] [Abstract][Full Text] [Related]
36. Apoptosis regulation by Bcl-x(L) modulation of mammalian inositol 1,4,5-trisphosphate receptor channel isoform gating.
Li C; Wang X; Vais H; Thompson CB; Foskett JK; White C
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12565-70. PubMed ID: 17636122
[TBL] [Abstract][Full Text] [Related]
37. Cancer cell death strategies by targeting Bcl-2's BH4 domain.
de Ridder I; Kerkhofs M; Veettil SP; Dehaen W; Bultynck G
Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118983. PubMed ID: 33549704
[TBL] [Abstract][Full Text] [Related]
38. Calcium trafficking integrates endoplasmic reticulum function with mitochondrial bioenergetics.
Kaufman RJ; Malhotra JD
Biochim Biophys Acta; 2014 Oct; 1843(10):2233-9. PubMed ID: 24690484
[TBL] [Abstract][Full Text] [Related]
39. Bcl-2 interaction with the inositol 1,4,5-trisphosphate receptor: role in Ca(2+) signaling and disease.
Distelhorst CW; Bootman MD
Cell Calcium; 2011 Sep; 50(3):234-41. PubMed ID: 21628070
[TBL] [Abstract][Full Text] [Related]
40. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.
Vervloessem T; Sasi BK; Xerxa E; Karamanou S; Kale J; La Rovere RM; Chakraborty S; Sneyers F; Vogler M; Economou A; Laurenti L; Andrews DW; Efremov DG; Bultynck G
Cell Death Dis; 2020 Sep; 11(9):769. PubMed ID: 32943617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
